Barclays PLC Has $640,000 Stock Holdings in Codexis, Inc. (NASDAQ:CDXS)

Barclays PLC grew its stake in shares of Codexis, Inc. (NASDAQ:CDXS - Free Report) by 51.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 207,628 shares of the biotechnology company's stock after purchasing an additional 70,255 shares during the quarter. Barclays PLC owned approximately 0.26% of Codexis worth $640,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Intech Investment Management LLC bought a new stake in Codexis in the 3rd quarter valued at about $66,000. Marshall Wace LLP bought a new stake in shares of Codexis during the second quarter valued at approximately $89,000. Algert Global LLC raised its holdings in shares of Codexis by 17.1% during the second quarter. Algert Global LLC now owns 41,556 shares of the biotechnology company's stock valued at $129,000 after buying an additional 6,069 shares during the last quarter. Squarepoint Ops LLC boosted its position in shares of Codexis by 113.8% during the second quarter. Squarepoint Ops LLC now owns 74,531 shares of the biotechnology company's stock worth $231,000 after buying an additional 39,664 shares during the period. Finally, GSA Capital Partners LLP grew its holdings in Codexis by 83.5% in the 3rd quarter. GSA Capital Partners LLP now owns 99,629 shares of the biotechnology company's stock worth $307,000 after buying an additional 45,337 shares in the last quarter. 78.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $11.00 target price on shares of Codexis in a research note on Friday, November 22nd. Benchmark restated a "hold" rating on shares of Codexis in a research note on Monday, November 4th.

Codexis Price Performance

NASDAQ:CDXS traded up $0.08 during midday trading on Friday, hitting $5.00. 638,754 shares of the stock were exchanged, compared to its average volume of 670,050. The company has a market capitalization of $406.90 million, a price-to-earnings ratio of -5.75 and a beta of 2.13. The company has a current ratio of 3.21, a quick ratio of 3.15 and a debt-to-equity ratio of 0.39. Codexis, Inc. has a one year low of $2.53 and a one year high of $6.08. The business has a 50-day moving average price of $4.78 and a two-hundred day moving average price of $3.71.

Codexis (NASDAQ:CDXS - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.04). Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. The firm had revenue of $12.83 million during the quarter, compared to the consensus estimate of $11.64 million. During the same period in the prior year, the firm posted ($0.26) EPS. Sell-side analysts predict that Codexis, Inc. will post -0.77 EPS for the current year.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.